Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotrecogin Alfa (Activated) in Submassive Pulmonary Embolism
NCT00191724Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2004
- Primary completion
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of drotrecogin alfa in pulmonary embolism (PE) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Major Bleeding Events. Started Sep 2004; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00191724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191724.